Narcolepsy
别名
Narcolepsy with or without cataplexy
近两年的全球研究 2,684L2
2024/08 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。
- 2026-08Telemedicine Consultation as Diagnostic Triage for Adult and Children With Suspected Narcolepsy: A Reliability and Diagnostic Accuracy Study
- 2026-08Targeting Orexin 2 Receptors in Idiopathic Hypersomnia and Narcolepsy: A Randomised Phase 1b Proof-Of-Concept Study of Alixorexton
- 2026-08Global and Partial Cataplexy, Geste Antagoniste, and Startle Response in Narcolepsy Type 1
- 2026-08综述病例报告Hypersomnia
- 2026-07综述Therapeutic potential of targeting the orexin (hypocretin) system in sleep disorders
- 2026-07Small molecule orexin agonist ROXA-47 enhances learning and memory in mice
- 2026-07综述Current and Emerging Therapies for Pediatric Sleep Disorders: A Narrative Review
- 2026-07Differences in Sleep Spindle Characteristics Between Children With Narcolepsy and Those With Other Causes of Subjective Sleepiness
- 2026-07Pharmacological Provocation Tests With Sodium Channel Blockers in Suspected Brugada Syndrome: Are Current Guidelines Missing Cases?
- 2026-07Molecular Signatures of Ferroptosis in Sleep Disorders: A Comparative Analysis of GPX4, ACSL4, and TfR1
- 2026-07Reply to "Unexpectedly higher mortality in non‑type 1 narcolepsy: diagnostic heterogeneity or unmeasured confounders?"
- 2026-07综述Guidelines for daily sodium intake: a counterpoint to the current recommendation for low sodium intake
- 2026-07综述Optimizing patient outcomes and empowering the patient-clinician partnership
- 2026-07'I had to change my way of thinking, change my emotions, and learn how to react': A narrative study on the management of narcolepsy symptoms and coping with the disease from patients' perspectives
- 2026-07Hidden burden and economic vulnerability of Narcolepsy Patients - Accessibility as the major challenge for a new therapeutic era
- 2026-07Oxytocin promotes socially triggered cataplexy
- 2026-07From radioimmunoassay to mass spectrometry: redefining hypocretin/orexin measurement in narcolepsy
- 2026-07综述The gut-sleep connection: a scoping review into microbiome alterations in sleep-wake and circadian disorders
- 2026-07Reply to "Veteran status as an underappreciated confound in narcolepsy mortality"
- 2026-07Reply to "The question of whether narcolepsy increases mortality should be answered based on reliable studies"
国家医保药品目录中点名本病的药品 1L2
出自《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》（医保发〔2025〕33号，2026-01-01 起执行）。下列药品在药品名称或限定支付范围里出现了本病的名称。
匹配不到 ≠ 不能报销。目录里只有约一成药品设了限定支付范围，其余按适应症正常使用同样可报销；本区块只能回答「目录有没有点名这个病」，不能回答「这个病有没有药能报销」。各省执行细则、双通道与单独支付范围另有规定，请以当地医保部门口径为准。
- 盐酸替洛利生片乙类谈判药品限发作性睡病6岁及以上患者。
境外已获批用于本病的药物 8L2
欧盟 3 项、美国 5 项。同一药物在两地各批一次的，会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径，各有各的条件与费用。这一节能确定地告诉你的只有一件事：这个病在世界范围内已经有获得批准的药物，它叫什么名字。拿这个名字去问主治医生，是下一步最省力的做法。
药名一律保留英文原文，不作翻译——中国的药品通用名与英文名的音译经常不一致，译错会让人去找一个不存在的药。
- Xyrem欧盟2005-10-13sodium oxybate官方记录
- Wakix欧盟2016-03-31pitolisant官方记录
- Sunosi欧盟2020-01-16solriamfetol官方记录
- Provigil美国1998-12-24Modafinil官方记录
- Xyrem美国2002-07-17sodium oxybate官方记录
- Sunosi美国2019-06-17Solriamfetol官方记录
- WAKIX美国2019-08-14Pitolisant官方记录
- Xywav美国2020-07-21calcium, magnesium, potassium, and sodium oxybates官方记录
已获孤儿药资格、尚未获批的在研药物（11 项）
孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励，不代表这个药已被证明有效，也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
- Mazindol欧盟2015-10-09Treatment of narcolepsy官方记录
- tropatepine hydrochloride欧盟2022-03-16Treatment of narcolepsy官方记录
- sodium oxybate欧盟2023-10-13Treatment of narcolepsy官方记录
- N-{(2S,3R)-4,4-Difluoro-1-(2-hydroxy-2-methylpropanoyl)-2-[(2,3',5'-tr欧盟2023-11-08Treatment of narcolepsy官方记录
- alixorexton欧盟2026-05-20Treatment of narcolepsy官方记录
- Gamma hydroxybutyrate美国1987-12-03Treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.官方记录
- mazindol美国2016-07-06Treatment of narcolepsy官方记录
- pentetrazol美国2017-03-16Treatment of narcolepsy官方记录
- reboxetine美国2018-10-15Treatment of narcolepsy官方记录
- 4-((L-valyl)oxy)butanoic acid美国2019-06-12Treatment of Narcolepsy官方记录
- oveporexton美国2026-03-02treatment of narcolepsy type 1 (narcolepsy with cataplexy)官方记录
数据来自欧洲药品管理局（EMA）的药品与孤儿药资格公开导出表，以及美国 FDA 孤儿药资格数据库。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。
在中国开展的临床试验 13L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。
登记为可入组 6
- 招募中NCT06279247Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy中国研究中心 1 个：Jinan
- 招募中NCT06797284The Impact of Light, Electrical, and Magnetic Neuroregulation Interventions on Sleep-wake Disorders中国研究中心 1 个：Suzhou
- 招募中NCT06952699A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)中国研究中心 4 个：Beijing、Changchun、Guangzhou、Shanghai
- 招募中NCT07493265A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy中国研究中心 8 个：Beijing、Changchun、Guangdong、Guangzhou、Jinan、Nanchang 等 8 地
- 招募中NCT07633301A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)中国研究中心 3 个：Beijing、Guangzhou、Zhengzhou
- 招募中NCT07727239Temporal Interference Stimulation of Hypothalamus in Patients With Narcolepsy Type 1中国研究中心 1 个：Xi'an
其他状态的试验（7 项）
- 已完成NCT00061022Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke中国研究中心 3 个：Beijing、Guangzhou、Shanghai
- 状态未知NCT03376568Investigation of Clinical Feature and Brain Function in Narcoleptic Patients中国研究中心 1 个：Xi'an
- 已终止NCT04096560A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy中国研究中心 4 个：Beijing、Changchun、Shanghai、Tianhe
- 状态未知NCT04940806The Value of Combined Detection of Orexin-A, HLA Gene, PSG and MSLT in the Evaluation of Patients With Narcolepsy中国研究中心 1 个：Jinan
- 已完成NCT06241911Transcutaneous Auricular Vagus Nerve Stimulation in Patients With Narcolepsy Type 1中国研究中心 1 个：Xi'an
- 已完成NCT06505031A Study of TAK-861 in People With Narcolepsy Type 1中国研究中心 4 个：Beijing、Guangdong、Shanghai、Zhengzhou
- 进行中·不再招募NCT07654803Radar Sleep Monitoring in Type 1 Narcolepsy: Feasibility中国研究中心 1 个：Xi'an
中国境外的在招试验 39L2
这些试验在中国没有研究中心，通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处：看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生，或据此进一步查该药是否已在境外获批、是否有拓展性用药（expanded access）通道。
美国19法国14西班牙7意大利6加拿大5荷兰5澳大利亚5比利时3德国3日本2瑞士2芬兰2捷克1挪威1另有 1 个国家/地区
CT.gov 报告命中 39 项，此处取回并展示最近的 15 项。
- 尚未开始招募NCT07766343Hypersomnia in the Paediatric Population法国
- 招募中NCT07540897A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)加拿大、美国
- 招募中NCT06383806Decreasing Nightmares in Adults With Narcolepsy美国
- 尚未开始招募NCT07625280A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH美国
- 尚未开始招募NCT07540364A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE)
- 招募中NCT07646678A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia日本
- 招募中NCT07675135A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy美国
- 招募中NCT07598708A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence美国
- 招募中NCT07584434A Phase 1, First-in-human Study of VX-433美国
- 招募中NCT07502443A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2比利时、加拿大、法国、意大利、荷兰、西班牙、美国
- 招募中NCT07455383A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1澳大利亚、比利时、加拿大、法国、荷兰、美国
- 招募中NCT07365566Pain Assessment in Patients With Idiopathic Rapid Eye Movement (REM) Sleep Behaviour Disorder法国
- 招募中NCT07363720A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy法国、德国、意大利、荷兰、西班牙、瑞士、美国
- 招募中NCT07299097Epidemiology of Narcolepsy Type 1 and Type 2 in Spain西班牙
- 招募中NCT06809803Extended-release Sodium Oxybate in Children美国
外部标识与链接
发现这一页有错误？告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学：Orphanet（CC BY 4.0）
- 中文病名：Orphanet 中文包，冻结于 2020-06-01；本条目在该版本中无中文名
- 表型中文标签：HPO 简体中文翻译（CHPO 上游成果）